Dossier - Page 1 - FirstWord Reports

Learn More Indication-level Pricing: Payer Insights

Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...

Compare
Learn More MSL Teams: Field Force size and structure (2019)

What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...

Compare
Learn More Real World Data and Evidence: Payer Insights

Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...

Compare
Learn More The Impact of Drug Compounding on Pharma

Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma? Drug compounding is a fast growing sector meeting the needs...

Compare
Learn More Review of Influence: The Institute for Clinical and Economic Review (ICER)

As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...

Compare
Learn More The Future of CRISPR

Where will CRISPR deliver real value? Investors and pharma are enthusiastic about CRISPR gene editing technology: not only can it be used to develop new therapeutics, it has become a powerful tool in drug discovery,...

Compare
Learn More Trends in Pharma-Patient Engagement

Exactly how is Pharma organising and benefitting from its patient engagement strategy? How are patient engagement teams structured and resourced? When do teams engage with patients and what are the main...

Compare
Learn More Trends in Digital Pharma Marketing

What are the trends and developments that will drive pharma's digital marketing initiatives? What are the trends that are shaping digital pharma marketing? How will increased investment be used to drive the digital...

Compare
Learn More Innovative drugs: Mapping the Pricing and Reimbursement Landscape

Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the US–but only...

Compare
Learn More Market Access Team Structure and Function – Industry Survey (2019)

How are market access teams developing to meet evolving stakeholder demands? What are the trends that are defining market access skills? Which core competencies should teams be developing for the future? What market...

Compare
Learn More Pharma-Tech Partnerships: Key Success Factors

What does an ideal Pharma-Tech partnership look like? Learn from Merck, Sanofi, Boehringer Ingelheim and UCB With tech companies making their presence felt in the health market and a demand for greater efficiency...

Compare
Learn More Commercialisation of Biosimilars: Current Best Practice and Future Trends

The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...

Compare
Learn More Charting Real World Data and Evidence - Activity and Capabilities (2018)

How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...

Compare
Learn More The State of Pharma Digital Transformation

How digitally mature is pharma? What progress has pharma made to embrace the digital age? Are digital strategies robust enough? Are appropriate capabilities and organisational structures in place? How culturally ready...

Compare
Learn More Time to Market: Accelerating Market Access

Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...

Compare
Learn More Virtual Clinical Trials: The future of drug development?

How viable are virtual clinical trials as a model for conducting clinical research? With our deepening understanding of disease and ever more targeted therapies, slow and costly traditional clinical trials alone are no...

Compare
Learn More A new Era in Pharma Marketing: Delivering Content-Driven Experiences

Are you locked in a traditional product marketing mind set? Time to move on... How can you provide better support and awareness to HCPs and patients for your brands? Content marketing may be the answer. Advocates argue...

Compare
Learn More Medical-grade Wearable Technology: Applications and implications for pharma

Leveraging clinical wearables and digiceuticals to gain competitive advantage From smart wristbands and glasses to tiny sensors in pills, the latest advances in medical-grade technology are unlocking new opportunities...

Compare
Learn More Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...

Compare
Learn More Pharma-patient engagement: Patient centricity comes of age

Are you truly patient-centric or just ticking boxes? Find out how your strategy compares Until relatively recently, patient centricity was commonly seen as just a useful talking point and the catalyst for some...

Compare

Browse by